GREY:NEPTF - Post by User
Comment by
goldstoryon Aug 05, 2014 3:03pm
459 Views
Post# 22810913
RE:RE:RE:enzy
RE:RE:RE:enzy
MIGDAL HA'EMEQ, Israel, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (
ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the second quarter ended June 30, 2014.
......
" For the six months ended June 30, 2014, selling and marketing expenses increased to $4.2 million from $3.3 million for the same period a year ago, primarily as a result of building the sales infrastructure of VAYA Pharma USA in order to expand sales to additional states and
due to license amortization expenses related to the settlement and license agreement signed with Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc."
......